RT Book, Section
A1 Seder, Christopher W.
A1 Liptay, Michael J.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Burt, Bryan M.
A2 Groth, Shawn S.
A2 Loor, Gabriel
A2 Wolf, Andrea S.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1170409929
T1 Techniques for Staging and Restaging of Non–Small-Cell Lung Cancer
T2 Sugarbaker’s Adult Chest Surgery, 3e
YR 2020
FD 2020
PB McGraw-Hill Education
PP New York, NY
SN 9781260026931
LK accesssurgery.mhmedical.com/content.aspx?aid=1170409929
RD 2024/04/20
AB Lung  cancer  is  the  leading  cause  of  cancer-related  mortality,  accounting  for  26%  of  all  deaths  from  malignancy  in  the  United  States  annually.1  When  a  patient  is  known  or  suspected  to  have  non–small-cell  lung  cancer  (NSCLC),  determining  the  extent  of  the  disease  spread  or  stage  is  necessary  to  choosing  the  optimal  treatment  strategy.  If  no  evidence  of  extrathoracic  disease  exists,  understanding  the  involvement  of  the  mediastinal  lymph  nodes  is  critical  to  assigning  stage.  Since  treatment  recommendations  for  NSCLC  rely  heavily  on  tumor  stage,  it  seems  intuitive  that  accurate  staging  would  be  standard.  However,  it  has  been  repeatedly  demonstrated  that  proper  staging  of  NSCLC  is  not  routinely  performed.2–4